TET2 and renal cell carcinoma: Peng Ding found that the loss of TET2 reduced the infiltration of T cells and suppressed cytokine and chemokine expression, consequently stimulating TET2 activity, and this effect can be exploited to improve immunotherapy in renal cell carcinoma.